三级片视频播放,精品三级片在线观看,A级性爱视频,欧美+日韩+国产+无码+小说,亲子伦XX XX熟女,秋霞最新午夜伦伦A片黑狐,韩国理伦片漂亮的保拇,一边吃奶一边做边爱完整版,欧美放荡性护士videos

The Neurofilament Light Chain （NfL）, a ~68 kDa protein encoded by the NEFL gene, is a critical structural component of the neuronal cytoskeleton, predominantly expressed in large myelinated axons of the central and peripheral nervous systems. As part of the neurofilament family （including NfM and NfH chains）, NfL forms heteropolymers that stabilize axonal structure, regulate axon diameter to modulate nerve conduction velocity, and facilitate intracellular transport by acting as a scaffold for organelles and signaling molecules. Its release into biofluids （e.g., cerebrospinal fluid and blood） following neuronal injury or degeneration has established NfL as a highly sensitive, disease-agnostic biomarker of neuroaxonal damage. Elevated NfL levels correlate with diverse neurological conditions, including neurodegenerative diseases （Alzheimer’s, Parkinson’s, ALS）, neuroinflammatory disorders （multiple sclerosis, neuromyelitis optica）, stroke, and traumatic brain injury. Notably, NfL rises before clinical symptoms emerge, enabling early detection, while baseline concentrations predict disease progression and outcomes. Reductions in NfL levels are increasingly used to monitor therapeutic efficacy in clinical trials, such as antisense oligonucleotide therapies for ALS. Ultrasensitive assays like Simoa allow noninvasive blood-based quantification, enhancing its utility for longitudinal monitoring. With high sensitivity, accessibility, and broad applicability, NfL has become pivotal in advancing diagnostics, prognostics, and personalized treatment strategies for neurological disorders.